ArticleFEBS open bio2023

CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.

Zhaohui Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.